[CrossRef] 147. Prior, I.A.; Lewis, P .D.; Mattos, C. A Comprehensive Survey of Ras Mutations in Cancer. Cancer Res. 2012 ,72, 2457–2467. [CrossRef] 148. Tran, E.; Robbins, P .F.; Lu, Y.-C.; Prickett, T.D.; Gartner, J.J.; Jia, L.; Pasetto, A.; Zheng, Z.; Ray, S.; Groh, E.M.; et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 2016 ,375, 2255–2262. [CrossRef] 149. Olivier, M.; Hollstein, M.; Hainaut, P . TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harb. Perspect. Biol. 2010 ,2, a001008. [CrossRef] 150. Lo, W.; Parkhurst, M.; Robbins, P .F.; Tran, E.; Lu, Y.-C.; Jia, L.; Gartner, J.J.; Pasetto, A.; Deniger, D.; Malekzadeh, P .; et al. Immunologic Recognition of a Shared P53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunol. Res. 2019 ,7, 534–543. [CrossRef] 151. Kim, S.P .; Vale, N.R.; Zacharakis, N.; Krishna, S.; Yu, Z.; Gasmi, B.; Gartner, J.J.; Sindiri, S.; Malekzadeh, P .; Deniger, D.C.; et al. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-Cell Receptor-Engineered T Cells Targeting Common P53 Neoantigens in Human Solid Tumors. Cancer Immunol. Res. 2022 ,10, 932–946. [CrossRef] 152. Hsiue, E.H.-C.; Wright, K.M.; Douglass, J.; Hwang, M.S.; Mog, B.J.; Pearlman, A.H.; Paul, S.; DiNapoli, S.R.; Konig, M.F.; Wang, Q.; et al. Targeting a Neoantigen Derived from a Common TP53 Mutation. Science 2021 ,371, eabc8697. [CrossRef] 153. Waitkus, M.S.; Diplas, B.H.; Yan, H. Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell 2018 ,34, 186–195. [CrossRef] [PubMed] 154. Schumacher, T.; Bunse, L.; Pusch, S.; Sahm, F.; Wiestler, B.; Quandt, J.; Menn, O.; Osswald, M.; Oezen, I.; Ott, M.; et al. A Vaccine Targeting Mutant IDH1 Induces Antitumour Immunity. Nature 2014 ,512, 324–327.